CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study
about
The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in BelgiumT-Helper 17 Cell Cytokine Responses in Lyme Disease Correlate With Borrelia burgdorferi Antibodies During Early Infection and With Autoantibodies Late in the Illness in Patients With Antibiotic-Refractory Lyme Arthritis.Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease.The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome.Induction of IL-10 by Borrelia burgdorferi is regulated by the action of CD14-dependent p38-MAPK and cAMP-mediated chromatin remodeling.Neuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist's Clinical Practice
P2860
CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CCL19 as a Chemokine Risk Fact ...... spective Clinical Cohort Study
@en
CCL19 as a Chemokine Risk Fact ...... pective Clinical Cohort Study.
@nl
type
label
CCL19 as a Chemokine Risk Fact ...... spective Clinical Cohort Study
@en
CCL19 as a Chemokine Risk Fact ...... pective Clinical Cohort Study.
@nl
prefLabel
CCL19 as a Chemokine Risk Fact ...... spective Clinical Cohort Study
@en
CCL19 as a Chemokine Risk Fact ...... pective Clinical Cohort Study.
@nl
P2093
P2860
P356
P1476
CCL19 as a Chemokine Risk Fact ...... spective Clinical Cohort Study
@en
P2093
Alison W Rebman
Catriona A Wagner
John N Aucott
Kathleen T Bechtold
Lauren A Crowder
Mark J Soloski
William H Robinson
P2860
P304
P356
10.1128/CVI.00071-16
P577
2016-09-06T00:00:00Z